Aug 24, 2026 —
Rznomics, a South Korea-based clinical-stage biopharmaceutical company focused on RNA-based gene therapies, has joined Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated by Eli Lilly to help biotechnology companies advance their science while remaining independent.
Through LGL, member companies gain access to laboratory and office infrastructure and proximity to Lilly’s research ecosystem — support intended to accelerate candidate discovery and development. For Rznomics, the move is aimed at speeding progress of its RNA-based gene therapy pipeline across oncology and genetic diseases.
The collaboration reflects continued investment in RNA-based genetic medicines alongside established viral-vector and cell-therapy modalities.
